Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963748 | 0.94 | FBP1 (0.39) | FBP1NPY5RCNR2BACE1RAB9A | |
| SCHEMBL966058 | 0.88 | TP53 (0.38) | CNR2RAB9ACNR1NPC1TP53 | |
| SCHEMBL4554505 | 0.86 | NPY5R (0.34) | NPY5RRAB9ATP53F10 | |
| SCHEMBL5115435 | 0.86 | KMO (0.38) | RAB9ANPC1TP53KMT2A | |
| SCHEMBL963019 | 0.86 | TP53 (0.37) | FBP1CNR2RAB9ACNR1NPC1 | |
| SCHEMBL4554288 | 0.81 | TP53 (0.38) | CNR2RAB9ACNR1NPC1TP53 | |
| SCHEMBL4554438 | 0.80 | MAPK8 (0.35) | RAB9ATP53 | |
| SCHEMBL963610 | 0.80 | IRAK4 (0.35) | RAB9ANPC1TP53POLBKMT2A | |
| SCHEMBL964859 | 0.80 | IRAK4 (0.35) | CNR2RAB9ANPC1TP53KMT2A | |
| SCHEMBL4554652 | 0.80 | GABRA1 (0.36) | NPY5RTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | FBP1 74/4885NPY5R 1067/4885CNR2 2360/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | FBP1 1241/4885NPY5R 764/4885CNR2 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.